La cadena de opciones muestra datos clave de las opciones de acciones de Abpro Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Abpro Hldgs..

Abpro Hldgs (NASDAQ:ABP) Bolsa, Cadena de Opciones

Abpro Hldgs

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Quantum,Computing,Concept,,Quantum,Mechanics,,Advanced,Technology,,Artificial,Intelligence,And

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

HCTI

IXHL

KLRS

LGPS

ORGN

PTIX

QUBT

SATL

SPCE

TSSI

TVTX

Descubre las acciones que destacan en el premercado de EE. UU.: Quantum Computing sube tras superar expectativas, mientras otras caen.

Acciones de Quantum Computing (QUBT) se disparan un 12%; aquí están 20 acciones que se mueven en premercado

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

VYNE Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Company's Phase 1b clinical trial in the treatment of moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases.&nbsp; &nbsp;
VYN202 Program Update In April, the FDA placed a clinical hold on the Company's Phase 1b trial following an observation of testicular toxicity in dogs from a non-clinical toxicology study of VYN202. A No-Observed-Adverse-Effect Level (NOAEL) was established covering all clinical doses in females. The FDA has lifted the clinical hold for female patients on the 0.25 mg and 0.5 mg doses in this Phase 1b psoriasis trial. The 1 mg dose was not included at this time in the revised protocol submitted to the FDA due to its lower toxicological safety margin as compared to the 0.25 mg and 0.5 mg doses. Sufficient data from a 12-week non-clinical toxicology study of VYN202 in dogs would be required in order to resume the trial in male clinical subjects, and the design of this toxicology study has been agreed upon with the FDA.
Following the clinical hold, VYNE made the decision to unblind the clinical data from the subjects who were enrolled in the study (VYN202 treated: n=6 across 0.25 mg, 0.5 mg and 1 mg doses; Placebo treated: n=1).
The Company believes that the totality of the data from this study, together with promising results from multiple preclinical models, support the continued advancement of VYN202 into serious, immune-mediated diseases with limited effective treatment options. Based on this assessment, the Company will no longer enroll patients in the Phase 1b psoriasis study, extending the Company's expected cash runway into the fourth quarter of 2026. VYNE expects to provide further updates on its plans for the VYN202 program following the release of top-line results from the ongoing Phase 2b study of its lead candidate repibresib gel (formerly VYN201), a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo.

VYNE

VYNE Therapeutics Issues Program Update For VYN202 Following Clinical Hold Issued By FDA In April For Phase 1b Clinical Trial In Treatment Of Moderate-To-Severe Plaque Psoriasis

Autonomous vehicles, or AVs, are no longer a distant dream or science fiction—they're hitting roads, farms and factories worldwide as breakthroughs in artificial intelligence spark a commercial revolution across <a href="https://www.benzinga.com/topic/autonomous-vehicles">a $1.2 trillion industry.</a>
In a report shared with clients on Tuesday, Bank of America indicated that AVs have reached a pivotal inflection point thanks to dramatic advances in AI, simulation, and computing power.
To date, autonomous robotaxis have completed 186 million commercial miles as of April 2025. These vehicles are now operating in seven global cities, with plans to expand into 20 additional markets in the near future.
&#8220;Autonomous vehicles are having their ‘ChatGPT moment' and are no longer a moonshot," said the bank&#8217;s analyst Martyn Briggs. 
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46204187/palantir-stumbles-solar-stocks-rally-as-senate-approves-tax-bill-whats-moving-markets-tuesday">Palantir Stumbles, Solar Stocks Rally As Senate Approves Tax Bill: What&#8217;s Moving Markets Tuesday?</a>
<h2 class="wp-block-heading">AI, Not Just Automation, Is Driving The AV Revolution</h2>
Unlike earlier generations of self-driving systems, which relied on hard-coded software and maps, the latest wave of AVs is driven by "physical AI," according to the report.
This includes neural networks that continuously learn from real-world data and simulation environments known as "digital twins," which drastically reduce the need for on-road testing.
New capabilities like language models are adding "reasoning and interpretability to driving decisions," Briggs said, while supercomputers integrated into vehicles are enabling autonomous driving in new geographies and use cases.
The cost to deploy AVs is also falling. Hardware, such as LiDAR sensors, is getting cheaper.
<h2 class="wp-block-heading">Market Potential: Not Just Cars—Everything That Moves</h2>
The AV market is broader than just robotaxis. While cars represent a $700 billion opportunity by 2040, Bank of America estimates the total addressable market doubles to $1.2 trillion when including autonomous trucks, public transit, agricultural and mining vehicles. 
Some off-road AVs are already commercially available, with reported gains of 30% in productivity and 50% labor cost savings in industries like agriculture and mining.
Robotrucks are set to disrupt the $4 trillion global freight market. Autonomous trucking is accelerating fast, with 90 active pilot programs worldwide—two-thirds of which target long-haul freight. 
Seven of these pilots are nearing commercialization, with the goal of large-scale rollouts by 2027. Briggs said the freight industry is poised for transformation as AVs address "structural challenges like driver shortages" while reducing costs.
The story is no longer just about cars: &#8220;Anything that moves could become autonomous," Briggs said.
<h3 class="wp-block-heading">How to Invest In Autonomous Vehicle Market: 28 Stocks To Watch</h3>
The Bank of America report identifies 28 publicly traded companies across six sub-sectors—vehicle manufacturers, mobility platforms, software, sensors, semiconductors and insurance—with a combined market cap of approximately $9 trillion.
Original Equipment Manufacturers (OEMs):
<ul class="wp-block-list">
<li>Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>): Dominates autonomous mining trucks</li>
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>): Precision farming with autonomous tractors</li>
<li>Toyota Motor Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TOYOF#OTC">TOYOF</a>) and Hyundai Motor Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMLF#OTC">HYMLF</a>): Partnered with Waymo and Aurora</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>): Advanced driver-assistance systems (ADAS) and autopilot EVs</li>
<li>Daimler Truck Holding AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DTGHF#OTC">DTGHF</a>): Global leader in heavy-duty autonomous trucks</li>
<li>Xiaomi Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>): Integrating LiDAR and autopilot tech into smart vehicles</li>
</ul>
Mobility Platforms:
<ul class="wp-block-list">
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): Expanding AV ride-hailing with Waymo, Aurora and WeRide partnerships</li>
</ul>
Software Providers:
<ul class="wp-block-list">
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): Building purpose-built AVs through Zoox</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>): Operating Waymo robotaxis across U.S. cities</li>
<li>Dassault Systemes SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DASTF#OTC">DASTF</a>): Offers digital twin simulations and AV design platforms</li>
<li>Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Pony.ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>): Operating robotaxis and robotrucks in China</li>
</ul>
Sensor Companies:
<ul class="wp-block-list">
<li>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>), Denso Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOF#OTC">DNZOF</a>), Allegro MicroSystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>): Supplying ADAS sensors, radar, and steering systems</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) and RoboSense (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XEDSF#OTC">XEDSF</a>): Global leaders in LiDAR tech</li>
</ul>
Semiconductor Leaders:
<ul class="wp-block-list">
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): AV chips, AI training, simulation, and supercomputing platforms</li>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>): Enabling computer vision and ADAS systems</li>
<li>Infineon Technologies AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNF#OTC">IFNNF</a>), STMicroelectronics NV (OTC:<a class="ticker" href="https://www.benzinga.com/stock/STMEF#OTC">STMEF</a>), Horizon Robotics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HRZRF#OTC">HRZRF</a>): Leading providers of AV-specific silicon and AI hardware</li>
</ul>
Insurance:
<ul class="wp-block-list">
<li>Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>): Developing AV insurance products tailored for new risk profiles. </li>
</ul>
Surprisingly, one name was notably absent from the Bank of America&#8217;s list of autonomous vehicle investment picks: Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). 
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46180484/nvidia-palantir-tech-stocks-to-buy-q3-2025-sectors">Nvidia, Palantir Fuel Historic Tech Rally — And It&#8217;s Far From Done</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Image: Midjourney

Analyst Color

Equities

Large Cap

Global

Econ #s

Analyst Ratings

Tech

ALGM

AMZN

APTV

BIDU

DASTF

DNZOF

DTGHF

GOOG

HRZRF

HSAI

HYMLF

IFNNF

MBLY

NVDA

NXPI

PONY

QCOM

STMEF

TOYOF

TSLA

XEDSF

XIACF

XPEV

XPNGF

Autonomous Vehicles Hit Their 'ChatGPT Moment' — Best Stocks To Watch Now

Compass Point analyst Dominick Gabriele initiates coverage on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Buy rating and announces Price Target of $80.

Price Target

Initiation

Compass Point Initiates Coverage On Block with Buy Rating, Announces Price Target of $80

GBX: 14% &#x7C; <a href="https://www.benzinga.com//node/46208298">Greenbrier shares are trading higher after the company reported better-than-expected Q3 financial results.</a>
&nbsp;
CNC: -29% &#x7C; <a href="https://www.benzinga.com/node/46216848">Centene shares are trading lower after the company withdrew its previous 2025 GAAP and adjusted diluted EPS guidance, including the underlying guidance elements.</a>
&nbsp;
ELWS: 125% &#x7C; <a href="https://www.benzinga.com/node/46127723">Earlyworks Co Receives Extensions By The Nasdaq Hearings Panel to Regain Compliance With Continued Listing Requirements</a>

ELWS

Market-Moving News for July 2nd

WIIM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurance stocks are trading lower in sympathy with Centene, which withdrew its 2025 guidance.

Centene shares are trading lower after the company withdrew its previous 2025 GAAP and adjusted diluted EPS guidance, including the underlying guidance elements.

Challenger Job Cuts (Jun) 47.999K, Down From 93.816K Prior

Alert signals reversal of early weakness in EQIX
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01203530/Screenshot-2025-07-01-at-4.32.31%E2%80%AFPM-1021x1024.png" alt="" class="wp-image-15203" /></figure>
Equinix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:28 AM on July 1st. a significant trading signal occurred for Equinix Inc. (EQIX) as it demonstrated a Power Inflow at a price of $786.99. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Equinix's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Equinix's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for EQIX,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
After Market Close UPDATE:
The price at the time of the Power Inflow was $786.99. The returns on the High price ($800.16) and Close price ($795.38) after the Power Inflow are respectively 1.7% and 1.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past performance is not indicative of future results

Technicals

Opinion

Signals

EQIX

Equinix Stock Up 1.7% After Key Trading Signal

Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025.
Including net proceeds from the sale of the PRV, the Company reported that unaudited cash, cash equivalents, restricted cash and short-term investments&nbsp;as of June 30, 2025 were approximately $225 million.

ABEO

Abeona Therapeutics Nets $155M From Voucher Sale

Compass Point analyst Giuliano Bologna initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Neutral rating and announces Price Target of $33.

CHYM

Compass Point Initiates Coverage On Chime Financial with Neutral Rating, Announces Price Target of $33

Hewlett Packard Enterprise Completes Juniper Networks Acquisition, Doubling Networking Business To Deliver AI-Driven, Cloud-Native IT Solutions

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), and enterprise SaaS, has signed an offer to acquire a California-based civil engineering and land surveying firm with a well established history of operations. This marks ZenaTech's first proposed transaction in the US West Coast or Southwest region, creating a strategic entry point into California ─ a high-value market for drone-based precision agriculture due to a massive agriculture economy, crop diversity, labor and water challenges, and an openness to innovation.

BMV:ZENA

ZENA

ZenaTech Signs Offer To Acquire California-Based Civil Engineering And Land Surveying Firm For Undisclosed Terms

LITM

Snow Lake Energy JV Taps Single Drilling For 38,000m Campaign At Pine Ridge Uranium Project In Wyoming, Launch Set For July 21

UMH Properties Converts 188 Homes To Rentals In Q2, Boosts Occupancy To 94.4%, Reports 17% Rise In Home Sales Revenue

Contracts

REKR

Rekor Systems Extends Rekor Command Contract With Central Texas Regional Mobility Authority; $1.4M, 5-Year Agreement

<ul>
<li>Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell's pivotal Phase 3 study</li>
<li>BriaCell's Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer &amp; Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as <a href="https://www.globenewswire.com/Tracker?data=ELk5asFc4W_pTsyQ_74TVh24-Mzlu6753otmRhYbVjyY5sprIiAS-FCWSq69QBhEyHCx7x9gRWFsf1ZNn9YK9-cgazU5ZhbrMYHuLV8qXbsa_A-lrOs-_dwvbkvY30jW">NCT06072612</a>): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.
BriaCell's pivotal Phase 3 clinical study is evaluating BriaCell's lead clinical candidate, Bria-IMT&#x2122;, plus immune check point inhibitor (CPI) versus physician's choice in advanced metastatic breast cancer (Bria-ABC).

BCTX

TSX:BCT

BriaCell Adds Two Key Large Cancer Centers To Ongoing Pivotal Phase 3 Clinical Study; Expects Completing Patient Enrollment In Late 2025 Or Early 2026 And May Report Top Line Data As Early As H1-2026

CME Group Reports Record Q2 ADV Of 30.2M Contracts, Driven By Interest Rates, Agriculture, Metals, And SOFR Futures Growth









Ask ChatGPT

JMP Securities analyst Nicholas Jones maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Market Outperform and raises the price target from $275 to $440.

CVNA

JMP Securities Maintains Market Outperform on Carvana, Raises Price Target to $440

BWMN

Bowman Enters Agreement To Acquire e3i Engineers, Financed Through Combination Of Cash, Seller Notes and Convertible Note; Bowman Anticipates Deal Will Initially Operate At Annualized Net Service Billing Run Rate ~$2M

Canaccord Genuity analyst Katie Lachapelle upgrades Energy Fuels (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) from Speculative Buy to Buy and raises the price target from C$9.5 to C$9.75.

Upgrades

UUUU

Canaccord Genuity Upgrades Energy Fuels to Buy, Raises Price Target to C$9.75

Health Care

Financing

Press Releases

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

Management

Abpro Statement on the Departure of Former CEO Ian Chan

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Maxim Group

Comments

Abpro Hldgs

Abpro Hldgs (ABP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL